

## Antibiotic Panels

Antimicrobial	<i>S. aureus</i> , Oxacillin Suscept- ible	<i>S. aureus</i> , Oxacillin Resistant	Coag Neg staphylo- coci, Oxacillin Susceptible	Coag Neg staphylo- coci, Oxacillin Resistant	<i>Enterococcus sp.</i>	<i>S. pneu- moniae</i>	Hemolytic strepto- coci, blood and CSF only	Hemolytic strepto- coci, NOT blood, CSF	Enteric GNB e.g. <i>E. coli</i> , <i>Klebsiella</i> , <i>Proteus</i>	<i>P. aeruginosa</i>	Non-fer- menting GNB, NOT <i>P. aeruginosa</i>
<b>Amikacin</b>									[X]	[X]	[X] (1)
<b>AMOX/CLAV</b>									[X]		
<b>Ampicillin</b>					X				X		
<b>Cefazolin (U)</b>									X (2)		
<b>Cefepime</b>									[X]	X	[X] (1)
<b>Ceftaroline</b>		X									
<b>Ceftazidime</b>						X (3)	X	X (4)	[X]	X	X
<b>Ceftriaxone</b>									[X]		
<b>Ciprofloxacin</b>									X (5)	X (5)	X (1,5)
<b>Clindamycin (NU,6)</b>	X (5)	X (5)	X (5)	X (5)					X		
<b>Daptomycin (NU,7)</b>		X		X							
<b>Erythromycin (NU,6)</b>	X (5)	X (5)	X (5)	X (5)		X		X (4)		X	X (1)
<b>Gentamicin</b>					X (8)						
<b>HL Gentamicin (NU)</b>					X (U)	X		X (4)		X	
<b>Levofloxacin</b>	X (5,6)	X (5,6)	X (5,6)	X (5,6)	[X]			X (4)	X (5)	X (5)	X (5)
<b>Linezolid</b>		X		X							
<b>Meropenem</b>					[X] (3)				[X]	[X]	[X] (9)
<b>Minocycline</b>											X (10)
<b>Nitrofurantoin (U)</b>	X	X	X	X	X					X	
<b>Oxacillin (NU,11)</b>	X	X	X	X							
<b>Penicillin</b>	X	X			X	X (3)	X	X			
<b>PIP/TAZO</b>									[X]	X	X (1)
<b>Rifampin (12)</b>	X	X	X	X							
<b>HL Streptomycin (NU)</b>					X (8)						
<b>Tetracycline</b>	X (5)	X (5)	X (5)	X (5)	X (U)	X			X (5)		X (5, U)
<b>Tobramycin</b>									X	X	X (1)
<b>TRIM/SULFA</b>	X (5)	X (5)				X (5)			X (5)		X (5)
<b>Vancomycin</b>		X		X	[X]	[X] (3)	X				

## Antibiotic Panels

### FOOTNOTES

'X', routinely reported; '[X]', drug is only reported when related narrow-spectrum drug(s) test as resistant.

AMOX/CLAV, amoxicillin/clavulanate; NU, NOT for urinary tract use; PIP/ TAZO, piperacillin/ tazobactam; TRIM/ SULFA, trimethoprim/ sulfamethoxazole; HL, High level; U, FOR urinary tract use ONLY.

- 1) Not reported on *Stenotrophomonas maltophilia* and *Burkholderia cepacia*.
- 2) Only reported on urinary isolates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*
- 3) Routinely reported on blood and CSF isolates.
- 4) Not reported on Group B hemolytic streptococcal urogenital tract isolates.
- 5) Not reported on CSF isolates.
- 6) Not reported on blood culture isolates.
- 7) Not reported on lower respiratory tract isolates.
- 8) Not to be used for mono-therapy: must be used with a susceptible cell wall-active agent e.g. ampicillin or vancomycin. For serious infections only e.g. endocarditis.
- 9) Routinely reported on *Acinetobacter spp.* and *Burkholderia cepacia*. Not reported on *Stenotrophomonas maltophilia*. Selectively reported on others.
- 10) Reported on *Stenotrophomonas maltophilia* only
- 11) Oxacillin predicts response to anti-staphylococcal penicillins, cephalosporins, beta-lactam/ beta-lactamase inhibitor combination agents and carbapenems including those active in the urinary tract; oxacillin is not itself an active UTI agent.
- 12) Not to be used for mono-therapy: must be used with a second, susceptible agent.